Every Form 4 that PTC Therapeutics, Inc. (PTCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTCT filings page.
PTC Therapeutics, Inc. (PTCT) director Michael Schmertzler reported that Section Six Partners, L.P., of which he is a general and limited partner, sold 2,500 common shares in two transactions on October 7, 2026: 2,447 shares at a weighted average $63.38 per share and 53 shares at $63.95. The 2,447-share price reflects multiple trades ranging from $62.89 to $63.88. Both sales were made under the partnership's written Rule 10b5-1 plan adopted May 14, 2026. The shares were held by the partnership; Schmertzler disclaims beneficial ownership except to the extent of his pecuniary interest. A separate entry lists 163,266 shares held directly.
PTC Therapeutics’ executive vice president and CLO Mark Elliott Boulding exercised options for 1,638 shares on October 5, 2026, at a $39.42 exercise price, then sold those shares at a weighted average $64.03. On October 6, he exercised options for 435 shares at $39.42 and sold them at a weighted average $64.16. The transactions were effected pursuant to a written Rule 10b5-1 plan adopted September 10, 2025. The sales comprised multiple trades at $64.00–$64.34 on October 5 and $64.00–$64.90 on October 6.
PTC Therapeutics, Inc. director Glenn Jr. MD, PhD Steele exercised 12,000 options at an exercise price of $11.23 per share on September 30, 2026, acquiring 12,000 common shares, then sold 12,000 common shares at $65.16 per share that day. The transactions were effected under a written Rule 10b5-1 plan adopted March 9, 2026. The options were currently exercisable; the reported option balance after the transaction was 0.
PTC THERAPEUTICS, INC. (PTCT) director Michael Schmertzler reported the indirect sale of 20,000 shares of common stock on September 16–17, 2026 through Section Six Partners, L.P., an entity of which he is a general and limited partner. The trades were executed under a Rule 10b5-1 plan adopted by Section Six Partners, L.P. on May 14, 2026, at weighted-average prices ranging from $65.99 to $68.84 per share in multiple transactions. Schmertzler disclaims beneficial ownership of the partnership-held shares except to the extent of his pecuniary interest, and separately reports 163,266 shares of PTCT common stock held directly.
PTC THERAPEUTICS, INC. (PTCT) reported that director Michael Schmertzler, through Section Six Partners, L.P., filed a Form 4 for indirect sales of a total of 20,000 shares of common stock on September 9–10, 2026 under a written Rule 10b5-1 trading plan adopted on May 14, 2026.
The shares are held by Section Six Partners, L.P., where Schmertzler is a general and limited partner, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) reported that director Michael Schmertzler, through Section Six Partners, L.P., with indirect ownership, sold a total of 25,000 shares of common stock on August 26–27, 2026 under a written Rule 10b5-1 plan adopted on May 14, 2026. The sales were open-market transactions at weighted average prices around $71.55–$73.18 per share, each executed in multiple trades within disclosed price ranges. Separately, Schmertzler directly held 163,266 shares of common stock as of August 26, 2026. He disclaims beneficial ownership of the Section Six Partners, L.P. shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) director Michael Schmertzler reported indirect sales of an aggregate 25,000 shares of common stock on August 19–20, 2026. The sales were made by Section Six Partners, L.P., where he is a general and limited partner, pursuant to a written Rule 10b5-1 plan adopted on May 14, 2026. The reported weighted average prices ranged from the low $70s to the mid $73s per share across multiple trade buckets. Schmertzler reports separate direct ownership of 163,266 shares of PTCT common stock and disclaims beneficial ownership of the partnership-held shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) executive vice president and CLO Mark Elliott Boulding exercised stock options for 2,813 shares of common stock at an exercise price of $25.69 per share and then sold those 2,813 shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. Following the option exercise, he held 16,876 stock options under that award, which was granted on February 15, 2024 and vests over four years. These transactions were effected pursuant to a written Rule 10b5-1 plan adopted on September 10, 2025.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 10,292 shares of common stock on 2026-08-04 at $68.57 per share. The sale was executed under an irrevocable sell-to-cover election pursuant to a Rule 10b5-1 trading plan to satisfy tax withholding obligations upon vesting of 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. Following this transaction, Klein directly holds 383,868 shares of common stock, which include 162 shares acquired through the employee stock purchase plan for the period ended 2026-06-30.
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026. Grants included 4,000 restricted stock units vesting in three equal annual installments from July 28, 2027, and 2,000 restricted stock units vesting on January 2, 2027. She was also granted stock options for 3,475 and 1,738 shares of common stock at an exercise price of $75.39 per share, vesting over 36 and six equal monthly installments respectively, with both option grants expiring on July 27, 2036.
PTC Therapeutics' chief financial officer Pierre Gravier automatically sold 3,494 shares of common stock on July 14, 2026 at $80.35 per share pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a 26,000 RSU grant. After this transaction, he directly holds 83,986 shares, including 162 shares acquired through the employee stock purchase plan.
PTC Therapeutics director Mary L. Smith exercised stock options for 15,834 shares of common stock at an exercise price of $42.95 per share and sold 15,834 shares in open-market transactions at $90.00 per share on July 9, 2026. The sales were effected pursuant to a written Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, she holds 21,813 shares of PTC Therapeutics common stock directly.
Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he holds 60,299 shares directly, 2,899 shares indirectly through his spouse, and 45,036 stock options granted January 3, 2025 that vest over four years and expire January 2, 2035.
PTC Therapeutics executive Mark Elliott Boulding reported both sales and option exercises in PTC THERAPEUTICS, INC. common stock. On July 6, 2026, he sold 5,079 shares in a series of open‑market transactions at weighted average prices spanning $82.76 to $86.73. These sales were executed under a written Rule 10b5‑1 trading plan adopted on September 10, 2025.
On the same date, he exercised stock options to acquire 5,039 shares at strike prices of $46.54 and $39.42. Following the transactions, Boulding directly owns 105,272 shares of PTC Therapeutics common stock, and the filing shows remaining stock options outstanding in multiple series.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead sold 46,774 shares of common stock in open-market trades while exercising stock options. The sales on July 6–7 were executed under a pre-set Rule 10b5-1 trading plan.
Almstead exercised options to acquire 46,774 shares at exercise prices of $38.10 and $39.42 per share, then sold equivalent amounts at weighted average prices in the mid‑$80s to high‑$80s. Following these transactions, he holds 60,299 shares directly and 2,899 shares indirectly through his spouse.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported an options exercise and pre-planned share sale. He exercised stock options to acquire 8,130 shares of common stock at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions at weighted average prices in the mid-$85 range, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he holds 60,137 shares of PTC Therapeutics common stock directly and 2,737 shares indirectly through his spouse.
PTC Therapeutics, Inc. chief technical operations officer Neil Gregory Almstead reported a series of option exercises and share sales in PTCT common stock. On June 24–25, 2026, he exercised stock options for a total of 26,283 shares at exercise prices including $38.10 and $39.42 per share.
Over the same two days, he sold 26,283 shares of common stock in open-market transactions at prices generally in the mid‑$80s, with individual sale prices such as $87.00 and weighted‑average prices around $85–$86 per share. Following these transactions, Almstead directly holds 60,137 shares of PTCT common stock.
The filing notes that these transactions were carried out under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre‑scheduled rather than timed discretionarily.
PTC Therapeutics’ Chief Technical Operations Officer Neil Gregory Almstead reported an options exercise and matching share sales in Common Stock. He exercised stock options for 23,749 shares at $25.69 per share, then sold 23,749 shares in open-market transactions at weighted average prices of about $80.61 and $81.21 per share under a written Rule 10b5-1 trading plan adopted on November 11, 2025. He also reports 2,737 shares of Common Stock held indirectly through his spouse.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an exercise-and-sell stock transaction. She exercised options to acquire 19,686 shares of common stock at $25.69 per share and sold 19,686 shares in the open market at $75.56 per share on the same date. After these transactions, she directly holds 70,199 shares of common stock and 15,314 stock options as shown in the derivative table. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sell transaction in company stock. On June 17, 2026, he exercised stock options to acquire a total of 10,522 shares of Common Stock at an exercise price of $46.54 per share.
On the same date he sold 10,462 shares in open-market transactions at weighted average prices around $78.50–$79.25 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,272 shares of PTC Therapeutics common stock.
PTC Therapeutics chief business officer Eric Pauwels exercised stock options and sold shares in pre-planned trades. On June 10, 2026, he exercised options to acquire 17,566 shares of Common Stock at $18.01 per share, then executed open-market sales totaling 21,277 shares at $75.00 per share. Following these transactions, he held 73,411 shares of Common Stock directly. The trades were carried out under a written Rule 10b5-1 plan adopted on February 25, 2026, indicating they were pre-scheduled rather than timed discretionarily.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and CLO, exercised stock options for 2,812 shares of Common Stock at $25.69 per share and, on the same date, sold 2,812 shares in open-market transactions at weighted average prices of $72.67 and $72.08. These trades were made under a pre-arranged Rule 10b5-1 plan. Following the transactions, he directly holds 105,212 Common Stock shares and 19,689 stock options.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported a mix of equity compensation and related tax sales. On May 13, 2026, he acquired 12,500 shares of common stock through earned performance-based RSUs after a pre-established milestone was certified.
Of these earned RSUs, 6,250 shares vested immediately on May 13, 2026 and another 6,250 shares are scheduled to vest on May 13, 2027. On May 14, 2026, a total of 12,572 shares of common stock were sold in open-market transactions solely to satisfy tax withholding obligations under an irrevocable sell-to-cover election. Following these transactions, Klein directly owned 393,998 shares of PTC Therapeutics common stock.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sale transaction in company stock. On May 8, 2026, he exercised stock options to acquire a total of 3,540 shares of common stock at an exercise price of $46.54 per share.
That same day, he executed open-market sales totaling 3,540 shares at prices ranging from approximately $78.00 to $79.31 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,212 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 2,850 shares of common stock at $70.91 per share. According to the filing, the shares were sold under an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 6,500 RSUs from a prior 26,000-RSU grant. After this transaction, Klein directly holds 394,070 shares, indicating a small, tax-driven reduction in his overall stake.
PTC Therapeutics executive Mark Elliott Boulding exercised stock options and sold shares in a pre-planned trade. He exercised options to acquire 2,265 shares of Common Stock at an exercise price of $39.42 per share and received 2,265 shares.
On the same date, he sold 822 shares at a weighted average price of $68.91 per share and 1,443 shares at a weighted average price of $69.75 per share, pursuant to a Rule 10b5-1 trading plan. After these transactions, he directly holds 105,212 shares of PTC Therapeutics Common Stock.
PTC Therapeutics, Inc. executive Lee Scott Golden reported an automatic sale of 829 shares of Common Stock at $67.99 per share. According to the disclosure, these shares were sold pursuant to an irrevocable sell-to-cover election to satisfy tax withholding obligations tied to the vesting of 2,100 restricted stock units (RSUs) from an April 24, 2023 grant of 8,400 RSUs. Following this tax-related sale, Golden directly holds 79,115 shares of PTC Therapeutics common stock, so the transaction represents a small portion of his overall reported holdings.
PTC Therapeutics, Inc. reported that Chief Technical Operations Officer Neil Gregory Almstead sold a total of 52,003 shares of common stock in open‑market transactions on 2026-04-01 at prices around $69 per share.
After these sales, he directly holds 60,137 shares of PTC Therapeutics common stock and indirectly holds 2,737 shares through his spouse. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
PTC Therapeutics director Jessica Caroline Chutter received new equity awards. On March 24, 2026, she was granted stock options for 3,475 and 2,896 shares of common stock at an exercise price of $64.54 per share, expiring on March 23, 2036.
She also received 4,000 restricted stock units that vest in three equal annual installments starting March 24, 2027, and 3,333 restricted stock units that vest with 1,000 shares on June 2, 2026 and 2,333 shares on January 2, 2027. All transactions reflect compensation-related grants rather than open-market purchases or sales.
PTC Therapeutics CEO Matthew B. Klein reported routine equity compensation activity and a related tax sale. He acquired 12,500 shares of common stock through earned restricted stock units tied to performance-based awards granted in December 2024. The company’s compensation committee certified achievement of a pre-established milestone as of March 11, 2026, causing these units to be earned.
Of the earned units, 6,500 shares vested immediately on March 11, 2026, with the remaining 6,500 scheduled to vest on March 11, 2027. On March 12, 2026, 2,662 shares were automatically sold at $64.08 per share under a pre-set “sell to cover” election to satisfy tax withholding obligations. Following these transactions, Klein directly holds 396,920 shares of PTC Therapeutics common stock.
PTC Therapeutics director Stephanie Okey exercised stock options and sold shares in a pre-planned transaction. On March 10, 2026, she exercised options to acquire 15,167 shares of common stock at an exercise price of $33.63 per share.
On the same date, she sold 15,167 common shares in open-market transactions at a sale price of $70.00 per share pursuant to a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, she holds 8,000 shares of PTC Therapeutics common stock directly.
PTC Therapeutics, Inc. director Stephanie Okey sold 6,333 shares of common stock in an open-market transaction on March 5, 2026 at $63.38 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 24, 2025. After this transaction, she directly holds 8,000 PTC Therapeutics shares.
PTC Therapeutics executive Lee Scott Golden reported an open-market stock sale. On March 5, 2026, the company’s EVP & Chief Medical Officer sold 10,000 shares of PTC Therapeutics common stock at a price of $63.38 per share.
The sale was executed under a written Rule 10b5-1 trading plan that Golden adopted on December 4, 2025. After this transaction, Golden directly owns 79,944 shares of PTC Therapeutics common stock.
PTC THERAPEUTICS, INC. executive Neil Gregory Almstead, the Chief Technical Operations Officer, reported an indirect open-market sale of common stock by his spouse. On March 5, 2026, his spouse sold 3,989 shares of common stock at $63.38 per share in a sale classified as an open-market or private transaction.
This transaction was carried out under a written Rule 10b5-1 trading plan adopted by Almstead on November 26, 2025. Following the sale, his spouse held 2,737 shares of common stock indirectly, while Almstead held an additional 112,140 shares of common stock directly.
PTC Therapeutics executive Mark Elliott Boulding, Executive VP and Chief Legal Officer, reported open-market sales of a total of 3,019 shares of common stock on February 19, 2026. The transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024, occurred at weighted-average prices of $68.54 and $69.82 per share, based on multiple trades within disclosed price ranges from $67.99 to $70.18. Following these sales, Boulding directly held 105,212 shares of PTC Therapeutics common stock.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an automatic sale of 2,494 shares of common stock. The shares were sold at an average price of $69.36 per share to cover tax withholding obligations tied to recently vested restricted stock units.
These shares relate to the vesting of 3,500 RSUs from a February 15, 2024 grant of 14,000 RSUs and 1,450 RSUs from a February 15, 2024 grant of 2,900 RSUs. After this tax-withholding sale, Utter directly holds 70,199 shares of PTC Therapeutics common stock.
PTC Therapeutics chief financial officer Pierre Gravier reported an automatic sale of 2,992 shares of common stock at $69.36 per share. After this transaction, he holds 87,318 shares directly. The shares were sold under an irrevocable sell-to-cover instruction to satisfy tax withholding on recently vested restricted stock units (RSUs) from prior grants.
PTC Therapeutics, Inc.'s chief business officer, Eric Pauwels, reported an automatic sale of 3,019 shares of common stock in an open-market transaction at a price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding obligations upon the vesting of previously granted RSUs.
After this transaction, Pauwels directly holds 77,122 shares of PTC Therapeutics common stock. The sale reflects tax-related withholding rather than a discretionary reduction of his overall equity position.
PTC Therapeutics, Inc. reported that Chief Executive Officer Matthew B. Klein automatically sold 7,371 shares of common stock at an average price of $69.36 per share. The sale was made under an irrevocable sell-to-cover election to satisfy tax withholding on the vesting of 17,500 restricted stock units from a February 15, 2025 grant of 70,000 RSUs. Following this tax-related sale, Klein owned 387,082 shares of PTC Therapeutics common stock directly.
PTC Therapeutics EVP & Chief Medical Officer Lee Scott Golden reported an automatic sale of 2,484 shares of common stock. The shares were sold on February 18, 2026 in open-market transactions at a price of $69.36 per share.
According to the filing, the sale was executed under an irrevocable "sell to cover" election to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock units (RSUs). After this transaction, Golden directly holds 89,944 shares of PTC Therapeutics common stock.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported automatic stock sales to cover taxes tied to restricted stock unit vesting. On February 18, he sold 3,121 shares of common stock at $69.36 per share, including 3,056 shares held directly and 65 shares held indirectly through his spouse.
These transactions were executed under irrevocable sell-to-cover elections made when the RSU grants were accepted, to satisfy tax withholding obligations. After these sales, Almstead held 112,140 shares directly and 6,726 shares indirectly through his spouse.
PTC Therapeutics executive Mark Elliott Boulding reported option exercises and share sales. On February 17, 2026, he exercised stock options for 2,813 shares of common stock at $25.69 per share, increasing his direct common stock holdings to 114,125 shares.
On February 17–18, 2026, he sold a total of 5,894 shares of common stock in open-market transactions at prices around $69.29–$70.13 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2024. A portion of the shares sold was automatically sold to cover tax withholding obligations related to vesting restricted stock units. After these transactions, he directly owned 108,231 shares of common stock and 22,501 stock options that are currently exercisable.
PTC Therapeutics senior vice president and chief accounting officer Christine Marie Utter reported an automatic sale of 1,034 shares of common stock on January 8, 2026 at $76.45 per share. The filing explains these shares were sold under an irrevocable "sell to cover" election to satisfy tax withholding obligations tied to the vesting of 2,900 restricted stock units from a January 7, 2022 grant of 11,600 RSUs. After this tax-related sale, she beneficially owned 72,693 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. chief business officer Eric Pauwels reported a series of planned stock sales in January 2026. The Form 4 shows multiple open-market sales of PTC Therapeutics common stock on January 8, 9, and 12, 2026, at weighted average prices around the mid‑$70s per share, with transaction prices including $76.42, $76.98, $76.45, $77.41 and $78.70 per share. These transactions were executed under a written Rule 10b5‑1 trading plan adopted on September 15, 2025, meaning they were pre‑scheduled rather than discretionary trades.
One sale of 1,454 shares on January 8, 2026, was automatically executed to cover tax withholding obligations tied to the vesting of 4,200 restricted stock units from a January 7, 2022 grant of 16,800 RSUs. After the reported transactions, Pauwels directly held 80,141 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. reported an insider share sale by its chief executive officer Matthew B. Klein. On January 8, 2026, he sold 2,514 shares of common stock at $76.45 per share. After this transaction, he beneficially owned 394,453 shares of PTC Therapeutics common stock in direct ownership.
The filing explains that these shares were automatically sold under an irrevocable “sell to cover” election to satisfy tax withholding obligations tied to the vesting of 5,250 restricted stock units (RSUs) from a January 7, 2022 grant of 21,000 RSUs. This indicates the sale was made to cover taxes due on equity compensation rather than as a discretionary open‑market sale of investment holdings.
PTC Therapeutics executive Golden Lee Scott reported an automatic share sale related to tax withholding. On January 8, 2026, Scott sold 866 shares of PTC Therapeutics common stock at $76.45 per share. After this transaction, Scott beneficially owned 92,428 shares of common stock in direct form.
According to the footnote, the sale was made automatically under an irrevocable "sell to cover" election entered into when the equity awards were granted. The sale was used to satisfy tax withholding obligations tied to the vesting of 3,539 restricted stock units (RSUs) from January 7, 2022 grants that originally totaled 14,155 RSUs. This indicates the transaction was administrative in nature and connected to previously granted equity compensation.
PTC Therapeutics executive Mark Elliott Boulding reported multiple open-market sales of company common stock. As Executive Vice President and Chief Legal Officer, he filed a Form 4 showing several sales on January 8 and 9, 2026 at per-share prices in the mid-to-high $70s. Individual transactions included sales such as 2,482 shares at a weighted average price of $76.56 and 1,521 shares at a weighted average price of $77.46, with all shares held directly.
After the reported sales, Boulding beneficially owned slightly more than 111,000 shares of PTC Therapeutics common stock. One block of 1,286 shares was automatically sold under an irrevocable “sell to cover” election to satisfy tax withholding tied to the vesting of 3,600 restricted stock units from a 2022 equity grant. The filing notes that the sales were carried out under a written Rule 10b5‑1 trading plan adopted on December 4, 2024, with several prices disclosed as weighted averages over narrow trading ranges.
PTC Therapeutics, Inc. reported insider share sales by its Chief Technical Ops Officer, Neil Gregory Almstead, related to tax withholding on equity awards. On January 8, 2026, Almstead automatically sold 881 shares of common stock at $76.45 per share under a sell-to-cover election tied to the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.
On the same date, 59 additional shares of common stock were automatically sold at $76.45 per share, held indirectly through his spouse, to cover taxes on the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. After these transactions, Almstead beneficially owned 115,196 shares directly and 6,791 shares indirectly through his spouse.
PTC Therapeutics senior executive Christine Marie Utter reported automatic stock sales linked to restricted stock unit (RSU) vesting. As SVP and Chief Accounting Officer, she sold 1,381 shares of common stock at $76.95 on January 6, 2026 and 1,235 shares at $77.45 on January 7, 2026.
According to the footnotes, both sales were made under irrevocable “sell to cover” elections entered into when the RSU grants were accepted, solely to satisfy tax withholding obligations on the vesting of 3,500 RSUs from separate 14,000‑share grants. After these transactions, she directly owns 73,727 shares of PTC Therapeutics common stock.
PTC Therapeutics’ chief financial officer, Pierre Gravier, reported an automatic sale of company stock tied to RSU vesting. On 01/06/2026, he sold 2,139 shares of PTC Therapeutics common stock at a price of $76.95 per share. The filing states these shares were sold pursuant to an irrevocable “sell to cover” election entered into when he accepted the grant, in order to satisfy tax withholding obligations on the vesting of 5,625 restricted stock units (RSUs) from a January 3, 2025 grant of 22,500 RSUs. Following this tax-related sale, he beneficially owned 90,310 shares of PTC Therapeutics common stock directly.